Welcome to Markets Desk, your midday read on what's moving markets and why.
Pressure in the Treasury market is easing today after a bruising session Tuesday that pushed the thirty-year yield to its highest level since two thousand two. Investors are taking a breath, but the underlying concern hasn't gone away — sticky inflation expectations continue to weigh on the long end of the curve, and any relief may prove temporary.
Shifting to pharma, Takeda is getting attention after its experimental psoriasis drug zasocitinib delivered strong results in three Phase three trials under the LATITUDE program. The drug showed superior skin clearance in adults with moderate-to-severe plaque psoriasis, a meaningful readout that strengthens Takeda's pipeline and puts competitive pressure on existing JAK inhibitor players in the dermatology space.
Also in biotech, Galderma is out with three-year data on Nemluvio for atopic dermatitis, and the durability story holds up. Sustained improvements in skin lesions, itch, sleep and quality of life across adults and adolescents suggest the drug isn't just effective short term — it has the kind of long-cycle profile that payers and prescribers look for when making formulary decisions.
That's the tape. Markets Desk, signing off the floor.
